This inventor holds 4 USPTO granted patents. Top assignee: The University of Texas System. Active years: 1996-2007.
Company Filing History:
Years Active: 1996-2007
Title: Innovations by Arun K Roy in Estrogen and Androgen Receptor Research
Introduction
Arun K Roy is a notable inventor based in San Antonio, TX (US). He has made significant contributions to the field of molecular biology, particularly in the development of ribozymes for targeting estrogen and androgen receptors. With a total of 4 patents, his work has implications for treating hormone-dependent tumors and conditions.
Latest Patents
One of his latest patents is focused on "Estrogen receptor site-specific ribozymes and uses thereof for estrogen dependent tumors." This invention provides highly specific hammerhead ribozymes that target human estrogen receptor mRNA. The ribozymes, designated RZ1 through RZ7, yield predictable mRNA cleavage products. The methods developed aim to inhibit estrogen-dependent tumor growth, particularly in breast cancer, utilizing these ribozymes either separately or in combination.
Another significant patent is "Ribozyme mediated inactivation of the androgen receptor." This invention offers synthetic ribozyme oligonucleotides that can be used alone or within constructs. The ribozyme gene provides methods for treating prostate hyperplasia and other androgen-dependent pathologies. This approach improves therapies for such diseases without causing significant hormonal imbalance or requiring surgical intervention.
Career Highlights
Arun K Roy is affiliated with the University of Texas System, where he continues to advance research in his field. His innovative work has garnered attention for its potential to revolutionize treatments for hormone-related conditions.
Collaborations
Some of his notable coworkers include Shuo Chen and Bandana Chatterjee, who contribute to the collaborative research environment at the University of Texas System.
Conclusion
Arun K Roy's contributions to the field of molecular biology through his innovative patents demonstrate his commitment to advancing medical science. His work on ribozymes targeting estrogen and androgen receptors holds promise for improving treatments for hormone-dependent diseases.